NASDAQ: RNXT
Renovorx Inc Stock Forecast, Predictions & Price Target

Analyst price target for RNXT

Based on 1 analyst offering 12 month price targets for Renovorx Inc

Min Forecast
$12.50+1,228.37%
Avg Forecast
$12.50+1,228.37%
Max Forecast
$12.50+1,228.37%

Should I buy or sell RNXT stock?

Based on 1 analyst offering ratings for Renovorx Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RNXT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates RNXT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their RNXT stock forecasts and price targets.

RNXT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-21

1 of 1

Forecast return on equity

Is RNXT forecast to generate an efficient return?

Company
101.81%
Industry
259.27%
Market
228.52%
RNXT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RNXT forecast to generate an efficient return on assets?

Company
73.39%
Industry
90.14%
RNXT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RNXT earnings per share forecast

What is RNXT's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.33
Avg 2 year Forecast
-$0.36
Avg 3 year Forecast
-$0.05

RNXT revenue forecast

What is RNXT's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$1.2M+34.16%
Avg 2 year Forecast
$4.6M+400%
Avg 3 year Forecast
$24.1M+2,492.78%
RNXT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RNXT revenue growth forecast

How is RNXT forecast to perform vs Biotechnology companies and vs the US market?

Company
184.25%
Industry
102.02%
Market
25.67%
RNXT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RNXT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RNXT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNXT$0.94$12.50+1,228.37%Buy
DYAI$0.95$3.00+215.79%Buy
SER$3.25$15.00+361.54%Buy
FGEN$8.42$43.00+410.69%Buy
RADX$4.75$15.50+226.32%Strong Buy

Renovorx Stock Forecast FAQ

Is Renovorx Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: RNXT) stock is to Buy RNXT stock.

Out of 1 analyst, 0 (0%) are recommending RNXT as a Strong Buy, 1 (100%) are recommending RNXT as a Buy, 0 (0%) are recommending RNXT as a Hold, 0 (0%) are recommending RNXT as a Sell, and 0 (0%) are recommending RNXT as a Strong Sell.

If you're new to stock investing, here's how to buy Renovorx stock.

What is RNXT's earnings growth forecast for 2025-2027?

(NASDAQ: RNXT) Renovorx's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.

Renovorx's earnings in 2025 is -$11,105,000.On average, 6 Wall Street analysts forecast RNXT's earnings for 2025 to be -$11,962,533, with the lowest RNXT earnings forecast at -$11,852,583, and the highest RNXT earnings forecast at -$11,929,548. On average, 6 Wall Street analysts forecast RNXT's earnings for 2026 to be -$13,084,020, with the lowest RNXT earnings forecast at -$22,627,658, and the highest RNXT earnings forecast at -$7,696,482.

In 2027, RNXT is forecast to generate -$1,869,146 in earnings, with the lowest earnings forecast at -$5,387,538 and the highest earnings forecast at $1,924,121.

What is RNXT's revenue growth forecast for 2025-2027?

(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 184.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.67%.

Renovorx's revenue in 2025 is $928,000.On average, 6 Wall Street analysts forecast RNXT's revenue for 2025 to be $45,629,145, with the lowest RNXT revenue forecast at $31,786,472, and the highest RNXT revenue forecast at $58,200,067. On average, 5 Wall Street analysts forecast RNXT's revenue for 2026 to be $170,055,610, with the lowest RNXT revenue forecast at $143,667,671, and the highest RNXT revenue forecast at $198,056,146.

In 2027, RNXT is forecast to generate $881,833,629 in revenue, with the lowest revenue forecast at $287,335,341 and the highest revenue forecast at $1,346,884,413.

What is RNXT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: RNXT) forecast ROA is 73.39%, which is lower than the forecast US Biotechnology industry average of 90.14%.

What is RNXT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year RNXT price target, the average RNXT price target is $12.50, with the highest RNXT stock price forecast at $12.50 and the lowest RNXT stock price forecast at $12.50.

The Wall Street analyst predicted that Renovorx's share price could reach $12.50 by Nov 21, 2026. The average Renovorx stock price prediction forecasts a potential upside of 1,228.37% from the current RNXT share price of $0.94.

What is RNXT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: RNXT) Renovorx's current Earnings Per Share (EPS) is -$0.36. On average, analysts forecast that RNXT's EPS will be -$0.33 for 2025, with the lowest EPS forecast at -$0.32, and the highest EPS forecast at -$0.33. On average, analysts forecast that RNXT's EPS will be -$0.36 for 2026, with the lowest EPS forecast at -$0.62, and the highest EPS forecast at -$0.21. In 2027, RNXT's EPS is forecast to hit -$0.05 (min: -$0.15, max: $0.05).

What is RNXT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: RNXT) forecast ROE is 101.81%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.